Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.75 GBX | 0.00% | -6.25% | -53.12% |
Apr. 26 | Evgen Pharma plc will Change its Ticker to TCF from EVG | CI |
Apr. 26 | Evgen Pharma plc will Change its Name to TheraCryf plc | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's enterprise value to sales, at 2.1 times its current sales, is high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-53.12% | 4M | - | ||
-1.65% | 104B | B+ | ||
+6.75% | 97.47B | B+ | ||
+5.71% | 22.25B | B | ||
-12.60% | 21.68B | B+ | ||
-9.70% | 18.2B | A- | ||
-39.98% | 17.02B | A- | ||
-10.17% | 16.36B | B | ||
+6.12% | 14.39B | C+ | ||
+35.47% | 12.37B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EVG Stock
- Ratings Theracryf Plc